SMITHKLINE BEECHAM INFANRIX ACELLULAR RECOMMENDED FOR PRIMARY DTP VACCINATION SERIES BY FDA COMMITTEE; MEMBERS CITE LACK OF DATA ON DOSES 4 AND 5
SmithKline Beecham's Infanrix diphtheria-tetanus-acellular pertussis vaccine was unanimously recommended for approval for the three doses of a primary series of infant vaccination at two, four and six months of age by FDA's Vaccines & Related Biologicals Advisory Committee July 10.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth